For completeness of the evaluation, EFSA considered the proceedings abstract by Büchs et al. (2004) referred to in the report submitted by Bulgaria. However, due to limitations of the publication format and in the absence of sufficient information on the experimental design of the study and data generation and analysis, EFSA could not draw any conclusions on the reliability and relevance of this abstract for the present evaluation nor for the risk assessment of maize MON 810 in general. Therefore On 30 November 2011, the EFSA GMO Panel adopted a statement supplementing the environmental risk assessment conclusions and risk management recommendations on maize Bt11 cultivation (EFSA Panel on Genetically Modified Organisms, 2011b). In its statement, the EFSA GMO Panel concluded that "subject to appropriate management measures, maize Bt11 cultivation is unlikely to raise additional safety concerns for the environment compared to conventional maize" (EFSA Panel on Genetically Modified Organisms, 2011b). The EFSA GMO Panel considered that the environmental risk assessment conclusions and risk management recommendations on non-target Lepidoptera for maize Bt11 apply equally to maize MON 810 due to the similarities between both Bt maize events (i.e., identity of amino acid sequence of the core of the Cry1Ab protein, similar biological activity against susceptible Lepidoptera, similar Cry1Ab protein expression level in pollen).
The EFSA GMO Panel further supplemented its previous risk management recommendations on maize Bt11 and MON 810 cultivation by reapplying the mathematical model developed by Perry et al. (2010 Perry et al. ( , 2011 Perry et al. ( , 2012 , in order to consider additional hypothetical agricultural conditions, and to provide additional information on the factors affecting the insect resistance management (IRM) strategy (EFSA Panel on Genetically Modified Organisms, 2012d). , 2011a, 2012a, 2013c, 2014) . The EFSA GMO Panel noted shortcomings in the methodology for case-specific monitoring and general surveillance, and made recommendations to strengthen the annual PMEM activities on the GM maize. So far, the data submitted by the applicant in its PMEM reports did not indicate any adverse effects on human and animal health or the environment arising from the cultivation of maize MON 810.
Several EU Member States invoked safeguard clauses or emergency measures to provisionally restrict or prohibit the marketing of maize MON 810 on their territory. EFSA or its GMO Panel has been asked by the European Commission to evaluate whether the invocation was justifiable on the basis of the scientific information submitted in support of a safeguard clause or emergency measure. For all cases, EFSA or its GMO Panel concluded that, in terms of risk to human and animal health and the environment, no new scientific evidence had been presented that would invalidate its previous risk assessment conclusions on maize MON 810 (EFSA, 2004 (EFSA, , 2005 (EFSA, , 2006a (EFSA, , b, 2008a (EFSA, , b, c, d, 2014a EFSA Panel on Genetically Modified Organisms, 2012b , c, 2013a , b, 2014 . 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

CONTEXT OF THE SCIENTIFIC OUTPUT
The legislative framework regulating GMOs in the EU gives Member States the possibility to temporarily restrict the placing on the market of a GMO or its derived food and feed products on their territory or in the EU subject to indications of a clear and serious risk to the human and animal health or the environment. Member States invoking the so called 'safeguard clauses' under Article 23 of Directive 2001/18/EC or 'emergency measures' under Article 34 of Regulation (EC) 1829/2003 must justify their claims with new or additional scientific evidence that was made available after the consent for placing on the market of the GMO or its derived food and feed products was granted.
In this statement, EFSA evaluates, upon request of the European Commission, whether the documentation (a report and its complete list of references) submitted by Bulgaria justifies or invalidates its request to prohibit the cultivation of maize MON 810.
EFSA considers the concerns put forward by Bulgaria in the light of recent and relevant scientific publications. Concerns of Bulgaria related to co-existence and socio-economic aspects as well as regulatory-and policy-related documents listed in the report provided by Bulgaria are not considered in this statement as they fall outside the remit of EFSA and its GMO Panel.
EVALUATION
At the request of the European Commission, EFSA evaluated the concerns raised by Bulgaria and the accompanying documentation (a report and its complete list of references).
EFSA points out that the arguments put forward by Bulgaria in the aforementioned report do not reveal new scientific evidence in terms of risk to human and animal health or the environment. EFSA also notes that the peer-reviewed publications, referred to in the report, were addressed previously by EFSA or its GMO Panel in various scientific outputs on maize MON 810 or related Bt maize events expressing Cry1Ab protein (EFSA, 2004 (EFSA, , 2005 (EFSA, , 2006a (EFSA, , b, 2008a (EFSA, , b, c, d, 2014a EFSA Panel on Genetically Modified Organisms, 2012b , c, 2013a , b, 2014 . These publications are therefore not considered further in this statement.
The list of references cited by Bulgaria also contains a workshop proceedings abstract by Büchs et al. (2004) . Even though not recently published, the latter was considered by EFSA for completeness of the evaluation. However, owing to limitations of the publication format (an abstract) and in the absence of sufficient information on the experimental design of the study and data generation and analysis, EFSA could not draw any conclusions on the reliability and relevance of this abstract for the present evaluation nor for the risk assessment of maize MON 810 in general. In order to facilitate a thorough assessment of potential risks and quality appraisal of supplied studies, EFSA strongly 
